TEVA-DESVENLAFAXINE TABLET (EXTENDED-RELEASE)
国家: 加拿大
语言: 英文
来源: Health Canada
产品特点
(SPC)
18-10-2021
该产品的某些文档当前不可用，您可以向我们的客户服务发送请求，我们将在获得它们后尽快通知您。
发送请求。
发送请求。
有效成分:
DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE)
可用日期:
TEVA CANADA LIMITED
ATC代码:
N06AX23
INN（国际名称）:
DESVENLAFAXINE
剂量:
50MG
药物剂型:
TABLET (EXTENDED-RELEASE)
组成:
DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE) 50MG
给药途径:
ORAL
每包单位数:
30/100
处方类型:
Prescription
產品總結:
Active ingredient group (AIG) number: 0152509001; AHFS:
授权状态:
APPROVED
授权日期:
2022-02-14
产品特点
PRODUCT MONOGRAPH
Pr
TEVA-DESVENLAFAXINE
Desvenlafaxine Extended-Release Tablets
50 mg and 100 mg desvenlafaxine (as desvenlafaxine succinate)
Antidepressant
Teva Canada Limited
Date of Revision:
30 Novopharm Court
October 18, 2021
Toronto, Ontario
M1B 2K9
Control No.: 256177
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION..........................................................
3
SUMMARY PRODUCT INFORMATION
................................................................................3
INDICATIONS AND CLINICAL USE
.....................................................................................3
CONTRAINDICATIONS
.........................................................................................................3
WARNINGS AND PRECAUTIONS
.........................................................................................4
ADVERSE
REACTIONS........................................................................................................
11
DRUG INTERACTIONS
........................................................................................................
20
DOSAGE AND ADMINISTRATION
.....................................................................................
23
OVERDOSAGE
.....................................................................................................................
25
ACTION AND CLINICAL
PHARMACOLOGY.....................................................................
26
STORAGE AND STABILITY
................................................................................................
29
SPECIAL HANDLING INSTRUCTIONS
...............................................................................
29
DOSAGE FORMS, COMPOSITION AND
PACKAGING....................................................... 30
PART II: SCIENTIFIC INFORMATION
.............................................................................
31
PHARMACEUTICAL INFORMATION
.................................................................................
31
CLINICAL TRIALS
.......
阅读完整的文件
